LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Home・Akciju saraksts・Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

44.35 -0.49

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

43.91

Max

45.47

Galvenie mērījumi
By Trading Economics
Ienākumi	36M -2.3M
Pārdošana	-3.9M 208M
P/E Sektora vidējais	48.435 49.888
EPS	0.21
Peļņas marža	-1.104
Darbinieki	778
EBITDA	-72M 19M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+40.22% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-202M 2.6B
Iepriekšējā atvēršanas cena	44.84
Iepriekšējā slēgšanas cena	44.35

Ziņu noskaņojums

By Acuity

14%

86%

20 / 344 Rangs Healthcare

Supernus Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 8. jūn. 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

2026. g. 8. jūn. 15:41 UTC

Galvenie tirgus virzītāji

American Battery Shares Jump on Energy Department Victory

2026. g. 8. jūn. 23:46 UTC

Tirgus saruna

Nikkei May Rebound After Monday's Selloff -- Market Talk

2026. g. 8. jūn. 23:37 UTC

Tirgus saruna

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

2026. g. 8. jūn. 23:25 UTC

Tirgus saruna

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

2026. g. 8. jūn. 23:25 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 8. jūn. 21:57 UTC

Iegādes, apvienošanās, pārņemšana

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

2026. g. 8. jūn. 21:56 UTC

Iegādes, apvienošanās, pārņemšana

Salesforce Agrees to Buy m3ter

2026. g. 8. jūn. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 8. jūn. 19:22 UTC

Tirgus saruna

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

2026. g. 8. jūn. 19:01 UTC

Tirgus saruna

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

2026. g. 8. jūn. 18:52 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 8. jūn. 18:52 UTC

Tirgus saruna

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

2026. g. 8. jūn. 18:17 UTC

Tirgus saruna

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

2026. g. 8. jūn. 17:32 UTC

Tirgus saruna

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

2026. g. 8. jūn. 17:29 UTC

Tirgus saruna

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

2026. g. 8. jūn. 17:29 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 8. jūn. 16:55 UTC

Iegādes, apvienošanās, pārņemšana

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

2026. g. 8. jūn. 16:54 UTC

Iegādes, apvienošanās, pārņemšana

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

2026. g. 8. jūn. 16:40 UTC

Tirgus saruna

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

2026. g. 8. jūn. 16:31 UTC

Tirgus saruna

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

2026. g. 8. jūn. 16:27 UTC

Tirgus saruna

Mexican Inflation Seen Easing in May -- Market Talk

2026. g. 8. jūn. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 8. jūn. 16:03 UTC

Iegādes, apvienošanās, pārņemšana

Orange Bought Stake From Lorca

2026. g. 8. jūn. 16:01 UTC

Iegādes, apvienošanās, pārņemšana

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

2026. g. 8. jūn. 16:01 UTC

Iegādes, apvienošanās, pārņemšana

Orange Acquires 100% Ownership of MasOrange

2026. g. 8. jūn. 15:58 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 8. jūn. 15:58 UTC

Tirgus saruna

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

2026. g. 8. jūn. 15:55 UTC

Tirgus saruna

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

2026. g. 8. jūn. 15:41 UTC

Tirgus saruna

Gold Falls Below 200-Day Moving Average -- Market Talk

Salīdzinājums

Cenas izmaiņa

Supernus Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

40.22% augšup

Prognoze 12 mēnešiem

Vidējais 62.75 USD 40.22%

Augstākais 66 USD

Zemākais 55 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

4 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 4 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

20 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.